News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Dr. Reddy's Laboratories Ltd. (RDY) Announce Settlement of Clarinex(R) (Desloratadine) ANDA Patent litigation With Schering Corporation And Sepracor, Inc. (SEPR)


12/23/2008 8:35:24 AM

HYDERABAD, India--(BUSINESS WIRE)--Dr. Reddy's Laboratories today announced that it has entered into agreements with Schering and Sepracor which will allow Dr. Reddy’s to manufacture and market generic versions of the CLARINEX-D®-12 Hour and CLARINEX-D® -24 Hour products, with six months marketing exclusivity, and the CLARINEX® REDITABS® product, with six months marketing co-exclusivity, starting in 2012. Dr. Reddy’s will also market a generic version of the CLARINEX® 5 milligram tablet six months after the launch of the first generic version of that product.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES